LUC00140I1 - - Google Patents
Info
- Publication number
- LUC00140I1 LUC00140I1 LUC00140C LUC00140I1 LU C00140 I1 LUC00140 I1 LU C00140I1 LU C00140 C LUC00140 C LU C00140C LU C00140 I1 LUC00140 I1 LU C00140I1
- Authority
- LU
- Luxembourg
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8668708P | 2008-08-06 | 2008-08-06 | |
US15103609P | 2009-02-09 | 2009-02-09 | |
US17308809P | 2009-04-27 | 2009-04-27 | |
PCT/US2009/051879 WO2010017055A2 (fr) | 2008-08-06 | 2009-07-27 | Inhibiteurs de poly(adp-ribose)polymérase (parp) de type dihydropyridophtalazinone |
Publications (2)
Publication Number | Publication Date |
---|---|
LUC00140I1 true LUC00140I1 (fr) | 2019-12-13 |
LUC00140I2 LUC00140I2 (fr) | 2021-02-12 |
Family
ID=41129519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU00140C LUC00140I2 (fr) | 2008-08-06 | 2019-12-11 |
Country Status (31)
Country | Link |
---|---|
US (7) | US8012976B2 (fr) |
EP (3) | EP2326650B9 (fr) |
JP (3) | JP5984389B2 (fr) |
KR (1) | KR101846029B1 (fr) |
CN (3) | CN102171214B (fr) |
AR (1) | AR072970A1 (fr) |
AU (1) | AU2009279944B2 (fr) |
BR (1) | BRPI0917119B1 (fr) |
CA (1) | CA2732797C (fr) |
CY (3) | CY1115022T1 (fr) |
DK (2) | DK2326650T3 (fr) |
ES (2) | ES2466565T3 (fr) |
FR (1) | FR19C1071I2 (fr) |
GB (1) | GB2462361A (fr) |
HK (2) | HK1157755A1 (fr) |
HR (1) | HRP20170982T1 (fr) |
HU (2) | HUE035295T2 (fr) |
IL (1) | IL211070A (fr) |
LT (2) | LT2767537T (fr) |
LU (1) | LUC00140I2 (fr) |
MX (1) | MX2011001328A (fr) |
NL (1) | NL301021I2 (fr) |
NO (1) | NO2019042I1 (fr) |
NZ (1) | NZ591166A (fr) |
PL (2) | PL2767537T3 (fr) |
PT (2) | PT2767537T (fr) |
SG (2) | SG193842A1 (fr) |
SI (2) | SI2326650T1 (fr) |
TW (2) | TWI448464B (fr) |
WO (1) | WO2010017055A2 (fr) |
ZA (1) | ZA201100897B (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2326650B9 (fr) | 2008-08-06 | 2014-09-10 | BioMarin Pharmaceutical Inc. | Inhibiteurs de poly(adp-ribose)polymérase (parp) de type dihydropyridophtalazinone |
JP5753093B2 (ja) | 2008-12-19 | 2015-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼのインヒビターとして有用なピラジン誘導体 |
AU2011212928B2 (en) * | 2010-02-03 | 2016-06-23 | Medivation Technologies Llc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency |
US20110190266A1 (en) * | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
WO2011097602A1 (fr) * | 2010-02-08 | 2011-08-11 | Biomarin Pharmaceutical Inc. | Procédés de synthèse de dérivés de dihydropyridophtalazinone |
WO2011130661A1 (fr) * | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Méthodes d'utilisation d'inhibiteurs dihydropyridophthalazinoniques de la poly(adp-ribose) polymérase (parp) |
CN103228651A (zh) | 2010-05-12 | 2013-07-31 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物 |
SI2630146T1 (sl) * | 2010-10-21 | 2020-12-31 | Medivation Technologies Llc | Kristalinična tosilatna sol (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-IL)- 8,9-dihidro-2H-pirido(4,3,2-DE)ftalazin-3(7H)-ON |
WO2012166151A1 (fr) * | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Utilisation d'inhibiteurs de dihydropyridophtalazinone de poly(adp-ribose) polymérase (parp) dans le traitement d'un syndrome myélodysplasique (mds) et d'une leucémie myéloïde aiguë (aml) |
WO2013028495A1 (fr) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Inhibiteurs dihydropyridophthalazinone de poly (adp-ribose) polymérase (parp) pour le traitement du myélome multiple |
KR102184246B1 (ko) | 2011-09-30 | 2020-12-01 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 화합물의 제조 방법 |
IN2014CN02501A (fr) | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
WO2013097225A1 (fr) | 2011-12-31 | 2013-07-04 | Beigene, Ltd. | Dihydrodiazépinocarbazolones tétra ou pentacycliques fusionnés à utiliser en tant qu'inhibiteurs de parp |
MX2014008071A (es) * | 2011-12-31 | 2015-07-06 | Beigene Ltd | Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas. |
EP2804602A4 (fr) | 2012-01-20 | 2016-08-10 | Dennis Brown | Utilisation d'hexitols substitués, y compris le dianhydrogalactitol et ses analogues, pour le traitement de cellules souches de maladies néoplasiques et de cancers, y compris le glioblastome multiforme et le médulloblastome |
AU2013243291B2 (en) | 2012-04-05 | 2018-02-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
EP2918292B1 (fr) | 2012-11-08 | 2019-12-11 | Nippon Kayaku Kabushiki Kaisha | Composé polymère comprenant un composé camptothécine et un amplificateur de l'effet anti-cancéreux associé à celui-ci, et son utilisation |
LT2968316T (lt) | 2013-03-13 | 2019-10-25 | Forma Therapeutics Inc | 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ono dariniai ir susiję junginiai, kaip riebalų rūgšties sintazės (fasn) inhibitoriai, skirti vėžio gydymui |
US9993460B2 (en) | 2013-07-26 | 2018-06-12 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
EP3066084A1 (fr) | 2013-11-07 | 2016-09-14 | Medivation Technologies, Inc. | Intermédiaires de triazole utiles dans la synthèse de n-alkyltriazolecarbaldéhyde protégés |
CN103772395B (zh) * | 2014-01-23 | 2016-05-11 | 中国药科大学 | 一类具有parp抑制活性的化合物、其制备方法及用途 |
EP3125920B1 (fr) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol ou dibromodulcitol dans le traitement du carcinome non à petites cellules des poumons et du cancer des ovaires |
RU2736219C2 (ru) | 2014-06-17 | 2020-11-12 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации ингибиторов снк1 и atr |
BR112017001977A2 (pt) * | 2014-07-31 | 2017-11-21 | Medivation Technologies Inc | sal coformador, método de preparação de um sal coformador e composto |
CA2977685C (fr) | 2015-03-02 | 2024-02-20 | Sinai Health System | Facteurs de recombinaison homologue |
US9957267B2 (en) | 2015-07-01 | 2018-05-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
MX2018002322A (es) | 2015-08-25 | 2018-04-11 | Beigene Ltd | Procedimiento para la preparacion de un inhibidor de poli(adp-ribosa)polimerasa, formas cristalinas, y usos del mismo. |
AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
US9708319B1 (en) * | 2016-06-13 | 2017-07-18 | Yong Xu | Synthesis of PARP inhibitor talazoparib |
CN110087730B (zh) * | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
JP6541635B2 (ja) * | 2016-10-28 | 2019-07-10 | ベイジーン リミテッド | Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン |
CN108210461A (zh) * | 2016-12-16 | 2018-06-29 | 中国科学院上海药物研究所 | 一种Talazoparib药物组合物及其应用 |
CN107556312B (zh) * | 2016-12-29 | 2020-04-10 | 广州丹康医药生物有限公司 | 具有parp抑制活性的新型稠环化合物、其制备方法和用途 |
WO2018122168A1 (fr) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinaisons d'inhibiteurs de kinase bub1 et d'inhibiteurs de parp |
CN107573341B (zh) * | 2016-12-29 | 2020-08-14 | 广州丹康医药生物有限公司 | 作为parp抑制剂的新型稠环化合物、其制备方法和应用 |
WO2018157794A1 (fr) | 2017-02-28 | 2018-09-07 | Beigene, Ltd. | Formes cristallines de sels de dihydrodiazépinocarazolones téra-cycliques ou penta-cycliques fusionnés, et leurs utilisations |
WO2018205938A1 (fr) * | 2017-05-08 | 2018-11-15 | 广州丹康医药生物有限公司 | Inhibiteur de parp, composition pharmaceutique, procédé de préparation et utilisation associés |
EP3658560A4 (fr) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | Modulateurs de la somatostatine et utilisations de ces derniers |
EP3694551A1 (fr) | 2017-10-13 | 2020-08-19 | Merck Patent GmbH | Combinaison d'un inhibiteur de parp et d'un antagoniste de liaison d'axe pd-1 |
TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
CN110272419A (zh) * | 2018-03-14 | 2019-09-24 | 上海艾力斯医药科技有限公司 | 二氢吡啶并酞嗪酮衍生物、其制备方法及应用 |
CN108341792B (zh) * | 2018-04-28 | 2021-09-17 | 苏州莱克施德药业有限公司 | 一种Volasertib中间体1-环丙基甲基哌嗪的制备方法 |
CN108676888B (zh) * | 2018-07-12 | 2022-01-28 | 吉林大学 | 一种肺部恶性肿瘤易感性预测试剂盒及系统 |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
WO2020095184A1 (fr) | 2018-11-05 | 2020-05-14 | Pfizer Inc. | Combinaisons pour le traitement du cancer |
US11826430B2 (en) | 2019-05-14 | 2023-11-28 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
US20220227757A1 (en) | 2019-05-14 | 2022-07-21 | Suzhou Four Health Pharmaceuticals Co., Ltd. | Quinazoline-2,4-dione derivatives as parp inhibitors |
TW202131930A (zh) | 2019-11-13 | 2021-09-01 | 美商諾維雪碧歐公司 | 抗癌核荷爾蒙受體標靶化合物 |
CN111116514B (zh) * | 2020-01-10 | 2024-03-19 | 广州科锐特生物科技有限公司 | 一种1-环丙甲酰基哌嗪盐酸盐的制备方法 |
WO2021181233A2 (fr) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Protéines de fusion et leurs utilisations |
MX2023005641A (es) | 2020-11-13 | 2023-05-24 | Pfizer | Forma de dosificacion en capsula de gelatina blanda de talazoparib. |
CA3203814A1 (fr) | 2020-12-07 | 2022-06-16 | Pfizer Inc. | Procedes d'identification d'une tumeur sensible au traitement par le talazoparib et procedes de traitement associes |
BR112023019420A2 (pt) | 2021-03-23 | 2023-10-24 | Nuvation Bio Inc | Compostos de direcionamento ao receptor de hormônio nuclear anticâncer |
CA3214316A1 (fr) | 2021-03-24 | 2022-09-29 | Pfizer Inc. | Combinaison de talazoparib et d'un anti-androgene pour le traitement du cancer de la prostate metastatique sensible a la castration et mute par le gene ddr |
WO2022216979A1 (fr) * | 2021-04-08 | 2022-10-13 | Board Of Regents, The University Of Texas System | Composés et procédés pour le ciblage théranostique d'une activité parp |
EP4089093A1 (fr) * | 2021-05-12 | 2022-11-16 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Radiosynthèse de [18f] talazoparib |
WO2023131894A1 (fr) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Perte d'hétérozygotie génomique en tant que biomarqueur prédictif pour le traitement par le talazoparib et méthodes de traitement de cette perte d'hétérozygotie génomique |
WO2023201338A1 (fr) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de parp |
WO2023233295A1 (fr) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Dérivés de thiadiazolyle utilisés en tant qu'inhibiteurs d'adn polymérase thêta et leurs utilisations |
WO2023239789A1 (fr) * | 2022-06-08 | 2023-12-14 | Valo Health, Inc. | Inhibiteurs de parp de phtalazinone tricyclique et procédés d'utilisation |
CN115572218B (zh) * | 2022-08-29 | 2024-04-16 | 江阴勒森生物科技有限公司 | 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法 |
WO2024074959A1 (fr) | 2022-10-02 | 2024-04-11 | Pfizer Inc. | Combinaison de talazoparib et d'enzalutamide dans le traitement du cancer de la prostate résistant à la castration métastatique |
CN116283924A (zh) * | 2023-01-16 | 2023-06-23 | 四川效佳科技有限公司 | 一种药用级纯度的苯甲酸利扎曲普坦的重结晶方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US106631A (en) * | 1870-08-23 | Improvement in seed-planter | ||
US4415504A (en) | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
JPS58225065A (ja) | 1982-06-21 | 1983-12-27 | Nippon Shinyaku Co Ltd | 2−キノロン誘導体 |
US5328905A (en) * | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
CN1172502A (zh) | 1994-08-12 | 1998-02-04 | 亿万遗传股份有限公司 | 17q连锁的乳房癌和卵巢癌易患性基因的体内突变和多态性 |
ES2164136T5 (es) | 1994-08-12 | 2009-02-16 | The University Of Utah Research Foundation | Sondas de acidos nucleicos que copmrenden un fragmento del gen de susceptibilidad al cancer de mama y ovarios asociado a 17q. |
GB9505538D0 (en) | 1995-03-18 | 1995-05-03 | Ciba Geigy Ag | New compounds |
ID19155A (id) | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
DE19727410A1 (de) | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
TW430656B (en) | 1997-12-03 | 2001-04-21 | Dainippon Ink & Chemicals | Quinolinone derivative, method for preparing the same, and anti-allergic agent |
EP1077946A1 (fr) | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Composes condenses tricycliques inhibant l'activite de type poly(adp-ribose) polymerase (parp) |
DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
JP2001302669A (ja) * | 2000-04-18 | 2001-10-31 | Meiji Seika Kaisha Ltd | 三環性フタラジノン誘導体 |
JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
CN100348587C (zh) | 2002-02-19 | 2007-11-14 | 小野药品工业株式会社 | 稠合哒嗪衍生物化合物和含这些化合物作为活性成份的药物 |
EP1340819A1 (fr) | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Marqueurs de microsatellites |
GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
EP1400244A1 (fr) * | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase |
JPWO2004043959A1 (ja) | 2002-11-12 | 2006-03-09 | 持田製薬株式会社 | 新規parp阻害剤 |
AU2004220321B2 (en) | 2003-03-12 | 2010-02-25 | Kudos Pharmaceuticals Ltd | Phthalazinone derivatives |
US7268138B2 (en) * | 2003-05-28 | 2007-09-11 | Mgi Gp, Inc. | Compounds, methods and pharmaceutical compositions for inhibiting PARP |
WO2005080356A1 (fr) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Composes de tetrazole et leur utilisation comme antagonistes de recepteurs de glutamate metabotropiques |
GB0612971D0 (en) | 2006-06-30 | 2006-08-09 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
GEP20125379B (en) | 2007-05-03 | 2012-01-10 | Pfizer Ltd | 2 -pyridine carboxamide derivatives as sodium channel modulators |
CA2697246A1 (fr) | 2007-08-22 | 2009-02-26 | 4Sc Ag | Indolopyridines en tant qu'inhibiteurs de la proteine de fuseau kinesine (eg5) |
JP5439380B2 (ja) * | 2007-10-03 | 2014-03-12 | エーザイ インク. | Parp阻害化合物、組成物及び使用方法 |
CN101998959B (zh) | 2008-02-06 | 2013-08-28 | 生物马林药物股份有限公司 | 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂 |
EP2326650B9 (fr) | 2008-08-06 | 2014-09-10 | BioMarin Pharmaceutical Inc. | Inhibiteurs de poly(adp-ribose)polymérase (parp) de type dihydropyridophtalazinone |
US20110301350A1 (en) | 2008-08-12 | 2011-12-08 | Boehringer Ingelheim International Gmbh | Process for preparing cycloalkyl-substituted piperazine compounds |
AU2011212928B2 (en) | 2010-02-03 | 2016-06-23 | Medivation Technologies Llc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency |
US20110190266A1 (en) | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
WO2011097602A1 (fr) | 2010-02-08 | 2011-08-11 | Biomarin Pharmaceutical Inc. | Procédés de synthèse de dérivés de dihydropyridophtalazinone |
WO2011130661A1 (fr) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Méthodes d'utilisation d'inhibiteurs dihydropyridophthalazinoniques de la poly(adp-ribose) polymérase (parp) |
WO2011140009A1 (fr) | 2010-05-04 | 2011-11-10 | Biomarin Pharmaceutical Inc. | Procédés d'utilisation de glycopeptides semi-synthétiques en tant qu'agents antibactériens |
SI2630146T1 (sl) | 2010-10-21 | 2020-12-31 | Medivation Technologies Llc | Kristalinična tosilatna sol (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-IL)- 8,9-dihidro-2H-pirido(4,3,2-DE)ftalazin-3(7H)-ON |
WO2012166151A1 (fr) | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Utilisation d'inhibiteurs de dihydropyridophtalazinone de poly(adp-ribose) polymérase (parp) dans le traitement d'un syndrome myélodysplasique (mds) et d'une leucémie myéloïde aiguë (aml) |
WO2013028495A1 (fr) | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Inhibiteurs dihydropyridophthalazinone de poly (adp-ribose) polymérase (parp) pour le traitement du myélome multiple |
US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
EP3066084A1 (fr) | 2013-11-07 | 2016-09-14 | Medivation Technologies, Inc. | Intermédiaires de triazole utiles dans la synthèse de n-alkyltriazolecarbaldéhyde protégés |
BR112017001977A2 (pt) | 2014-07-31 | 2017-11-21 | Medivation Technologies Inc | sal coformador, método de preparação de um sal coformador e composto |
-
2009
- 2009-07-27 EP EP09805360.6A patent/EP2326650B9/fr active Active
- 2009-07-27 SG SG2013065719A patent/SG193842A1/en unknown
- 2009-07-27 US US12/510,096 patent/US8012976B2/en active Active
- 2009-07-27 JP JP2011522113A patent/JP5984389B2/ja active Active
- 2009-07-27 PL PL14154664T patent/PL2767537T3/pl unknown
- 2009-07-27 CN CN200980139634.2A patent/CN102171214B/zh active Active
- 2009-07-27 EP EP14154664.8A patent/EP2767537B1/fr active Active
- 2009-07-27 HU HUE14154664A patent/HUE035295T2/en unknown
- 2009-07-27 SI SI200930881T patent/SI2326650T1/sl unknown
- 2009-07-27 AU AU2009279944A patent/AU2009279944B2/en active Active
- 2009-07-27 PT PT141546648T patent/PT2767537T/pt unknown
- 2009-07-27 CA CA2732797A patent/CA2732797C/fr active Active
- 2009-07-27 BR BRPI0917119-3A patent/BRPI0917119B1/pt active IP Right Grant
- 2009-07-27 ES ES09805360.6T patent/ES2466565T3/es active Active
- 2009-07-27 NZ NZ591166A patent/NZ591166A/xx unknown
- 2009-07-27 EP EP17161893.7A patent/EP3241832A1/fr not_active Withdrawn
- 2009-07-27 MX MX2011001328A patent/MX2011001328A/es active IP Right Grant
- 2009-07-27 KR KR1020117005152A patent/KR101846029B1/ko active IP Right Grant
- 2009-07-27 PL PL09805360T patent/PL2326650T3/pl unknown
- 2009-07-27 DK DK09805360.6T patent/DK2326650T3/en active
- 2009-07-27 SI SI200931668T patent/SI2767537T1/sl unknown
- 2009-07-27 SG SG10201809895YA patent/SG10201809895YA/en unknown
- 2009-07-27 WO PCT/US2009/051879 patent/WO2010017055A2/fr active Application Filing
- 2009-07-27 LT LTEP14154664.8T patent/LT2767537T/lt unknown
- 2009-07-27 CN CN201410640197.5A patent/CN104478875B/zh active Active
- 2009-07-27 ES ES14154664.8T patent/ES2625817T3/es active Active
- 2009-07-27 PT PT98053606T patent/PT2326650E/pt unknown
- 2009-07-27 CN CN201410003342.9A patent/CN103896942A/zh active Pending
- 2009-07-27 DK DK14154664.8T patent/DK2767537T3/da active
- 2009-08-04 GB GB0913474A patent/GB2462361A/en not_active Withdrawn
- 2009-08-05 TW TW098126400A patent/TWI448464B/zh active
- 2009-08-05 TW TW103106940A patent/TW201422617A/zh unknown
- 2009-08-05 AR ARP090102999A patent/AR072970A1/es active IP Right Grant
-
2011
- 2011-02-03 ZA ZA2011/00897A patent/ZA201100897B/en unknown
- 2011-02-03 IL IL211070A patent/IL211070A/en active Protection Beyond IP Right Term
- 2011-03-31 US US13/077,785 patent/US8420650B2/en active Active
- 2011-11-04 HK HK11111926.3A patent/HK1157755A1/xx unknown
-
2013
- 2013-03-06 US US13/787,496 patent/US8999987B2/en active Active
-
2014
- 2014-03-28 CY CY20141100240T patent/CY1115022T1/el unknown
-
2015
- 2015-02-03 HK HK15101138.4A patent/HK1200813A1/xx unknown
- 2015-02-26 US US14/632,825 patent/US9820985B2/en active Active
- 2015-04-30 JP JP2015093417A patent/JP2015157843A/ja active Pending
-
2017
- 2017-05-31 CY CY20171100578T patent/CY1119218T1/el unknown
- 2017-06-29 HR HRP20170982TT patent/HRP20170982T1/hr unknown
- 2017-07-27 JP JP2017145036A patent/JP2018012698A/ja active Pending
- 2017-09-28 US US15/719,534 patent/US10543209B2/en active Active
-
2019
- 2019-11-28 NO NO2019042C patent/NO2019042I1/no unknown
- 2019-11-28 CY CY2019044C patent/CY2019044I1/el unknown
- 2019-12-03 FR FR19C1071C patent/FR19C1071I2/fr active Active
- 2019-12-05 LT LTPA2019522C patent/LTC2767537I2/lt unknown
- 2019-12-11 NL NL301021C patent/NL301021I2/nl unknown
- 2019-12-11 LU LU00140C patent/LUC00140I2/fr unknown
- 2019-12-13 US US16/714,474 patent/US10780088B2/en active Active
- 2019-12-19 HU HUS1900053C patent/HUS1900053I1/hu unknown
-
2020
- 2020-08-21 US US17/000,271 patent/US11364241B2/en active Active